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The overwhelming increase in the prevalence of overweight and obesity in recent years represents one of the greatest threats
to the health of the developed world. Among current treatments, however, gastrointestinal (GI) surgery remains the only
approach capable of achieving signiﬁcant weight loss results with long-term sustainability. As the obesity prevalence
approaches epidemic proportions, the necessity to unravel the mechanisms regulating appetite control has garnered signiﬁcant
attention. It is well known that physical activity and food intake regulation are the two most important factors involved in body
weight control. To regulate food intake, the brain must alter appetite. With this realization has come increased efforts to
understand the intricate interplay between gut hormones and the central nervous system, and the role of these peptides in
food intake regulation through appetite modulation. This review discusses the central mechanisms involved in body weight
regulation and explores a suite of well characterized and intensely investigated anorexigenic and orexigenic gut hormones.
Their appetite-regulating capabilities, post-GI surgery physiology and emerging potential as anti-obesity therapeutics are then
reviewed.
Nutrition and Diabetes (2012) 2, e26; doi:10.1038/nutd.2011.21; published online 16 January 2012
Keywords: obesity; appetite; hypothalamus; gut hormones
INTRODUCTION
The overwhelming increase in the prevalence of overweight and
obesity in recent years represents one of the greatest threats to the
health of the developed world.
1 Aside from the associated increases
in morbidity and mortality, the personal, societal and devastat-
ing economic consequences have been well documented.
2 Even
modest weight loss achieved through currently used approaches
can dramatically reduce these consequences, yet gastrointestinal
(GI) surgery remains the only treatment offering sustainable weight
loss results. Noteworthy, these results have, in part, been linked
to alterations in the physiology of circulating gut hormones and
their appetite-regulating capabilities.
3 In tandem with the realiza-
tion of the devastating global obesity epidemic and its related
co-morbidities over the last few decades, is the increasing recognition
and understanding of the intricate interplay between gut hormones
and the central nervous system (CNS),
4 and the regulation of food
intake through appetite modulation.
5 Several of these circulating
appetite modulators, including ghrelin, the only known orexigenic
gut hormone,
6 and a suite of anorexigenic gut hormones, including
cholecystokinin (CCK), pancreatic polypeptide (PP), peptide YY
(PYY), glucagon-like peptide (GLP)-1, and oxyntomodulin (OXM),
have been shown to inﬂuence appetite in humans.
7 As a result,
there has been increasing momentum aimed at turning this
evidence-based knowledge into practical anti-obesity intervention.
With all of the current approaches exhibiting problems,
3 and none,
except for GI surgery demonstrating long-term efﬁcacy,
8 post-GI
surgery gut hormone physiology and gut hormone administration
or co-administration may provide vital insight and prove to be
useful targets in the ongoing quest for safe and effective anti-
obesity therapies or treatments.
CENTRAL MECHANISMS IN BODY WEIGHT REGULATION
In the CNS, the hypothalamus is the key region involved in the
regulation of appetite.
1 It had previously been hypothesized that
satiety was controlled by the ventromedial hypothalamic nucleus,
and that feeding was controlled by the lateral region.
9 This early
hypothesis has, however, evolved into a much more comprehen-
sive and complex understanding of the integrated neural network
responsible for the regulation of appetite, involving discrete
pathways within speciﬁc nuclei of the hypothalamus,
1 and various
regulatory modulators.
10 The regulation of feeding, energy intake
and expenditure, and body weight is a homeostatic process.
11
Information regarding general health is communicated predomi-
nantly via long-term humoral signals, whereas meal initiation and
termination are believed to be regulated via short-term signals,
such as neural signals from the brain and humoral signals from the
gut.
12 The receipt and integration of these signals occur mainly in
the hypothalamus, and are largely regulated by the hypothalamic
arcuate nucleus (ARC), located at the base of the region.
1 Gut
hormone receptors are located on neuronal populations within
the ARC,
3 which is also partially accessible to circulating appetite
modulators due to its incomplete isolation from the blood-brain
barrier (BBB).
1 Within the ARC, there exists two distinct popula-
tions of neurons responsible for appetite regulation; the pro-
opiomelanocortin (POMC) appetite-inhibiting neurons and the
neuropeptide Y (NPY) and agouti-related peptide (AgRP) appetite-
stimulating co-expressing neurons.
13,14 Signals from the periphery
result in changes in the relative activity of these two neuronal
sub-populations and the release of their respective neuro-
peptides, subsequently inﬂuencing feeding behavior and energy
expenditure.
15
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Leptin
Early propositions surrounding the regulation of body weight
implicated body fat content as a key player in a so-called adipostat
mechanism,
16 which hypothesized the presence of an unknown
circulating factor capable of relaying information to the hypo-
thalamus. Several factors were subsequently proposed, but
inconclusively proven, until the revolutionary discovery of
leptin in 1994.
17 Expressed and secreted exclusively by white
adipose tissue adipocytes, the circulating levels of leptin are
proportional to fat mass.
1 Either peripheral or central adminis-
tration of leptin has been demonstrated to reduce food intake
and body weight and increase energy expenditure in rodents,
18
and activation of hypothalamic neurons expressing the leptin
receptor has suggested the mediation of its effects via this
central region.
1 Furthermore, leptin has been shown to inhibit
the orexigenic NPY/AgRP co-expressing neurons, and to stimu-
late the anorexigenic POMC-expressing neurons, within the
hypothalamic ARC.
19 Leptin represents one of the core compo-
nents of the physiological system that controls body weight in
mammals. Humans with leptin deﬁciency are obese,
20 and
decreased leptin production from white adipose tissue has been
demonstrated to contribute to a plethora of metabolic abnorm-
alities associated with visceral obesity.
21 A study in obese men
demonstrated that circulating leptin levels adjusted for body fat
were inversely correlated with body weight, suggestive of a leptin
deﬁcient state associated with obesity.
21 Therapies using leptin or
leptin agonists may, therefore, prove to be useful future tools
against obesity-related metabolic disturbances, and therapy
involving leptin replacement has to date been shown to result
in signiﬁcant weight loss.
22 Obesity, however, is also often
associated with increased circulating leptin levels.
23 This, com-
bined with the lack of expected corresponding leptin-mediated
effects, has given rise to the concept of leptin resistance.
24 In
many of these cases, despite high circulating levels and the
presence of functional receptors, the expected anorexigenic
effects of leptin are signiﬁcantly diminished.
25 Receptor over-
stimulation, and thus activation of negative feedback loops that
serve to block leptin signaling, has been proposed as a possible
contributing factor to the development of leptin resistance.
26
In diet-induced obese mice, the ability to reduce food intake
and thus body weight in response to peripheral leptin treatment
has been demonstrated.
26 In the same model, resistance has
been shown to eventually develop to even centrally-administered
leptin treatment,
27 and leptin-responsive neurons become incap-
able of activating downstream signaling pathways of the leptin
receptor.
26 Studies in obese rodents have also revealed an
impairment of leptin transport across the BBB as being closely
associated with leptin resistance.
25 This latter concept has given
rise to an alternative explanation wherein restrictive entry of
leptin across the BBB results in leptin insufﬁciency at its central




As an adiposity signal, insulin is believed to have a similar
lipostatic role to that of leptin, although its central effects on food
intake and energy homeostasis are less efﬁcient.
29 Similar to
leptin, circulating insulin levels are proportional to the degree of
adiposity.
30 Central administration of insulin in rodents has been
shown to reduce food intake and body weight,
31 and in the ARC,
insulin is thought to function through inhibition of NPY/AgRP
co-expressing neurons.
10 In addition to sharing some of the
appetite-regulating and lipostatic capabilities to that of leptin,
insulin is furthermore known to stimulate the synthesis and secre-
tion of leptin from white adipose tissue through a feedback loop
referred to as the adipo-insular axis.
32 There are some common
hypothalamic targets of leptin and insulin, and evidence of
common signal transduction pathways also suggests crosstalk
between the two hormones.
33 As with leptin, increased adiposity
can lead to a decrease in insulin sensitivity and a state of insulin
resistance.
34 Further to this traditional understanding of the
consequence of adiposity on insulin and its lipostatic effects, it is
also believed that adiposity might in fact be a consequence of
insulin resistance itself.
35 With the recognition and identiﬁcation
of insulin resistance as a potential underlying cause of various
metabolic abnormalities, particularly including obesity,
36 has
come increased investigation aimed at elucidating potential
insulin-sensitizing agents. Approaches aimed at improving insulin
sensitivity by way of pharmacological intervention remain a
driving force in drug development.
37 One such drug, metformin,
suppresses hepatic glucose production
38 and has been shown
to improve insulin sensitivity in humans.
39 Beneﬁcial weight-
stabilizing or weight-loss effects of this widely-used drug of choice





recently, however, certain data have challenged the safety of
these pharmacological approaches.
44 Alternative approaches, in
particular those involving plant-based medicinal compounds,
have, therefore, been intensely investigated for their potential
insulin-sensitizing capabilities. Berberine chloride has been shown
to function as an insulin-sensitizing natural product in diabetic
rats,
45 and an alcoholic extract of Artemisia dracunculus has shown
promising results in primary human skeletal muscle culture.
37
Insulin receptors have been identiﬁed in central areas linked to
food intake regulation,
46 and it is well established that, in addition
to sufﬁcient supply of insulin to the brain, insulin receptor function
is vital for energy homeostasis. As with the recently increasing
investigation focused on the discovery of insulin-sensitizing
agents, products aimed at improving insulin receptor function
have also been targeted. Natural products, such as the traditional
Chinese medicine Gynostemma pentaphyllum, have been shown
to improve glucose tolerance through enhancement of insulin
receptor sensitivity in obese diabetic rats,
47 leading to the
initiation of human clinical trials. Future research will undoubtedly
further elucidate safe and effective natural products as potential
insulin- and/or insulin receptor-sensitizers, but there remains
a wealth of work to be done in order to unveil the mechanisms of
these products.
GUT HORMONES AND OBESITY
The GI tract is the largest endocrine organ in the body and is
believed to have an important appetite-regulating role as a source
of various regulatory peptide hormones.
5,15 Post-prandial satiety is
believed to be regulated by a sensory system that communicates
between the gut and appetite-regulating centers in the brain, with
the hypothalamus being responsible for nutrient and energy
sensing and corresponding adjustments in food intake.
1 In the
gut, there exists a suite of endocrine cells, which synthesize and
release various hormones in response to nutrient and energy
intake,
1 and it has been demonstrated that these hormones
inﬂuence appetite in humans and rodents when administered at
physiological levels
7,48 (Table 1). Distinguishing between genuine
satiating effects and reductions in appetite due to nausea
or feelings of ill-health can potentially confound experimental
results. Food intake is inﬂuenced not only by nutritional status but
also by various palatability cues, including taste and smell.
49,50
Dose administration by way of oral gavage can be used to
mitigate potential aversion to taste and/or smell and effectively
allow for a more critical analysis of the outcomes of such studies.
Collectively, unlike leptin and insulin, which have been proposed
to signal long-term energy status, gut hormones are thought to
have a critical role in meal initiation and termination.
51,52
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CCK, the ﬁrst gut hormone reported to affect appetite,
53 has been
shown to dose-dependently reduce food intake in both rats
53 and
humans,
54 and in response to meal initiation, plasma levels have
been reported to rise within 15min.
55 Within the GI tract, CCK is
predominantly synthesized and released from the duodenum and
jejunum,
56 where its local regulatory effects include stimulation of
gallbladder contraction and inhibition of gastric emptying.
57 In
addition to its GI tract distribution, CCK is also widely distributed
within the hypothalamus, predominantly in the median eminence
and ventromedial nucleus, and represents the most abundant
neuropeptide in the CNS.
58 Centrally-administered CCK has been
shown to reduce food intake in rodents,
59 whereas peripheral
administration has been shown to reduce food intake in both
rodents and humans, through a reduction in meal size and
duration.
60 As a result, CCK has been investigated as a potential
therapeutic target for the management of obesity.
5 However,
compensatory increases in meal frequency,
61 the development
of tolerance following infusion (intraperitoneal),
62 and the short
half-life of the peptide
63 may undermine the therapeutic utility of
CCK. In addition, circulating levels in response to caloric ingestion
post-GI surgery have been reported as unchanged.
64 Two CCK
receptor subtypes have been characterized, including CCKA and
CCKB, in the GI tract and brain, respectively.
63 Of the two, evidence
exists for CCKA as being the more important regulator of food
intake,
65 and a reversal of the inhibitory effect on food intake
following administration of a CCKA antagonist in rats,
66 and
increased hunger and meal size in humans,
67 have been shown.
In recent years, the main area of therapeutic interest for
CCKA receptor agonists has been in obesity treatment.
68 In CCKA
receptor knockout rats, there is an elicited increase in meal size
and resultant onset obesity,
69 attributable to over-expression of
NPY neurons in the ARC.
70 The orally-active CCKA receptor agonist
Gl181771X has been shown to safely and effectively inhibit gastric
emptying in humans,
71 yet a 24 week double-blind randomized
study in obese subjects showed no net reduction in body weight
and no beneﬁcial effects on waist circumference.
72 Thus, as with
the therapeutic utility of CCK administration, CCKA receptor
monotherapy appears to hold minimal promise as a future anti-
obesity tool. The majority of research into the potential
therapeutic utility of CCK and orally-active CCK receptor ligands
has, however, taken place in only the last decade. Additional
human trials are required to support and strengthen the existing
data revealed through both animal and human studies, and future
investigations, perhaps involving co-administration with other
gut hormones, may be warranted.
Ghrelin
The 28--amino acid peptide hormone ghrelin, produced pre-
dominantly in the stomach,
73 represents the only known
orexigenic gut hormone identiﬁed to date.
5 Ghrelin binds to the
growth hormone secretagogue receptor which is highly expressed
in the hypothalamus and brain stem.
74 Although its signaling
mechanisms remain to be completely understood, a particularly
important role for the hypothalamic ARC and its NPY/AgRP co-
expressing neurons has been suggested.
75 Expression of the
growth hormone secretagogue receptor has been demonstrated
in NPY neurons,
76 and NPY and AgRP antagonists have been
shown to abolish ghrelin-induced feeding. Since its discovery in
1999,
73 ghrelin has been proposed to function as a meal initiator,
in part due to its potent appetite-stimulating effects in free-
feeding rats.
77 Ghrelin has also been shown to stimulate appetite
in both lean and obese humans,
78,79 and infusion (intravenous) in
healthy volunteers, at a concentration similar to that observed
after a 24h fast, has been shown to increase appetite and food
intake at a buffet-style meal by almost 30%.
1 Subcutaneous
injection has also been shown to signiﬁcantly induce appetite and
increase food intake.
80 In obese subjects, fasting ghrelin levels
have been shown to be lower compared with normal weight
controls and to rise following diet-induced weight loss.
81 The
typically expected post-prandial fall in circulating ghrelin levels is
also attenuated, or even absent in the obese,
82 suggestive of a
role of ghrelin in the pathophysiology of obesity.
83 In contrast,
circulating ghrelin levels have been reported as being markedly
reduced post-GI surgery, thus potentially enhancing the
weight-reducing effect of the procedure.
81 Since this initial study,
however, numerous other studies have reported no changes
84,85
and increases
86,87 in circulating fasting and post-prandial ghrelin
levels following GI surgery, thus highlighting the incomplete
understanding of the effect of the surgery on circulating levels of
this orexigenic gut hormone. More convincing evidence for the
role of ghrelin in energy homeostasis requires that blockage of its
signaling results in a decrease in body weight.
88 Pharmacological
blockage of ghrelin has been shown to result in decreases in food
intake and body weight in rodents,
77 and ghrelin- or ghrelin
receptor-deﬁcient rodents are resistant to diet-induced obe-
sity.
89,90 In diet-induced obese mice, the selective ghrelin receptor
antagonist YIL-870 has been shown to promote signiﬁcant
weight reduction through fat mass loss, attributable to the
centrally-mediated anorexigenic effects of blocking the growth
hormone secretagogue receptor.
91 More evidence is required in
support of these ﬁndings in humans. It is now well established
that ghrelin has a role in overall energy homeostasis, but
the pathways that mediate its effects and its role in the effects
of GI surgery require further characterization. Weight gain
prevention through pre-prandial receptor blockade may represent
the most promising role of ghrelin as a useful future anti-obesity
agent.
Pancreatic polypeptide
The 36-amino acid anorexigenic peptide PP, is primarily synthe-
sized and released from the endocrine pancreas,
15 and to a lesser
extent, from the colon and rectum.
5 Levels are low during the
fasting state and rise in proportion to caloric intake.
92 Interest in
the pharmacological targeting of the Y family of G protein-
coupled receptors as an anti-obesity strategy has grown
signiﬁcantly in recent years.
93 Although PP can function on all Y
receptors, it has been shown to have the highest afﬁnity for the Y4
receptor,
94 with food intake reduction being completely abolished
in Y4 receptor knockout rodents.
95 Peripherally-administered PP
reportedly leads to a reduction in food intake, in both rodents
and humans.
7,96 Peripheral PP administration has also been
demonstrated to lead to an increase in energy expenditure and
a reduction in body weight in rodents,
97 and a demonstrated
Table 1. Peripheral effects of selected food intake-regulating gut
hormones






CCK Intestinal L-cells CCKA Decrease
Ghrelin Stomach GHS Increase
PP Pancreas/colon Y4R Decrease
PYY Intestinal L-cells Y2R Decrease
GLP-1 Intestinal L-cells GLP1R Decrease
OXM Intestinal L-cells GLP1R? Decrease
Abbreviations: CCK, cholecystokinin; CCKA, cholecystokinin receptor
subtype A; GHS, growth hormone secretagogue receptor; GLP-1,
glucagon-like peptide-1; GLP1R, GLP-1 receptor; OXM, oxyntomodulin;
PP, pancreatic polypeptide; PYY, peptide YY; Y2R, PYY Y2 receptor;
Y4R, PP Y4 receptor.
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humans has shed further light on its potential anti-obesity utility.
7
The reported appetite- and energy balance-modulating effects of
PP Y4 agonism have been most notably attributed to indirect
actions via the brainstem, particularly through modulation of
digestive processes, yet the hypothalamus is also believed to
have a critical role in PP-mediated food intake reduction.
97 The
hypothalamic ARC, which is accessible to PP,
98 expresses Y4
receptors, and administration of PP over a 24h period in mice has
been shown to lead to a signiﬁcant reduction in NPY mRNA
expression.
97 Despite its demonstrated anorexigenic effects and
its possible anti-obesity utility, the exact hypothalamic nuclei and
downstream pathways through which PP Y4 agonism functions to
regulate food intake and body weight have, however, yet to be
fully elucidated.
99 A recent study in mice has demonstrated
the peripheral PP-mediated suppression of orexigenic pathways in
the lateral hypothalamic area, or ‘feeding centre’, and upregula-
tion of anorexigenic pathways in the ventromedial hypothalamus,
or ‘satiety centre’.
99 These effects were shown to be mediated via
the Y4 receptor, as they were not reproducible in Y4 receptor
knockout mice. Although the hypothalamically-regulated anorexi-
genic effects of PP remain to be fully characterized, a product
with the capacity to increase endogenous PP production while
avoiding degradation in the circulation, or to increase
Y4-mediated signaling, would certainly hold promise as a future
anti-obesity tool.
Peptide YY
PYY, a member of the PP-fold family of proteins to which PP also
belongs, is so named because of the tyrosine residues at both its
N- and C-termini.
100 The full-length 36-amino acid peptide is
synthesized and released from the L-cells of the GI tract, however,
most PYY in the circulation is in the 34-amino acid PYY336 form,
having been truncated at the N-terminus.
101 Circulating levels of
PYY336 are inﬂuenced by meal composition and calorie content,
and become elevated within 1h post-feeding.
102 Similar to PP,
peripherally-administered PYY336 exerts its food intake-inhibiting
effects via the Y family of G protein-coupled receptors, but with
preferentiality for the Y2 receptor.
103 Inhibition of food intake in
response to administration of a selective Y2 agonist,
104 and
attenuation of this inhibitory effect in response to Y2 antago-
nists,
105 have provided evidence for this ﬁnding. As circulating
PYY336 levels are often lower in the obese state, it has been
suggested that this characteristic may in fact have a causative role
in the development of obesity.
106 From a therapeutic utility
standpoint, PYY336 has been shown to have anorexigenic effects
in not only normal weight individuals, but also in the obese.
In a trial consisting of both lean and obese humans, PYY336
administration (intravenous) lead to a decrease in appetite and an
almost 30% restriction in caloric intake in both groups.
107 With the
anorexigenic capabilities of exogenous PYY336 being fully intact
in the obese, resistance is not thought to exist in the obese state,
and this has encouraged longer-term weight loss studies involving
chronic administration. Signiﬁcant increases in circulating
PYY336 levels have also been reported post-GI surgery,
108
possibly contributing to the initial and long-term sustainment
of weight loss attributed to the procedure. Development of a
PYY336 nasal spray for thrice daily administration has been shown
to result in modest weight reductions in humans,
109 however, side
effects including nausea and vomiting were encountered during
clinical trials. This, in addition to previously reported nausea and
conditioned taste aversion in mice in response to food intake-
lowering dosages,
110 has placed limitations on the utility
of PYY336 or Y2 receptor agonists as anti-obesity agents.
Development of more potent analogs, different administration
routes or dosing regiments, or novel combinatorial approaches
with other gut hormones may help unlock the future potential of
PYY336 as an anti-obesity therapy.
Glucagon-like peptide (GLP)-1
In the gut, GLP-1 is released from small intestinal and colonic
L-cells in proportion to ingested calories.
111 In both lean and
obese humans, peripherally-administered GLP-1 has been shown
to exert anorexigenic effects,
112,113 with other possible inﬂuences
on food intake being linked to a reduction in gastric emptying
and a suppression of gastric acid secretion.
114 Both centrally- and
peripherally-administered GLP-1 or GLP-1 receptor agonists have
been shown to enhance satiety, reduce food intake, and promote
weight loss in rodents and humans.
115- -117 Obese individuals have
been reported to elicit delays in the post-prandial release of GLP-1,
and thus present with reduced circulating levels of the peptide.
118
Nonetheless, they remain sensitive to peripherally-administered
GLP-1 and its anorexigenic effects.
113 As with PYY, GI surgery has
been shown to enhance the post-prandial GLP-1 response.
119
Because of inactivation and clearance by the enzyme dipeptidyl
peptidase-IV (DPP-IV), the half-life of GLP-1 is an estimated 5min,
5
thus presenting a major hurdle down the path to its possible
therapeutic utility. Currently investigated approaches against
the short half-life of GLP-1 include DDP-IV inhibition and the
development of more stable GLP-1 analogs.
120 Inhibition of DPP-IV
has had useful applications in the treatment of T2DM,
121 but less
promising results have been demonstrated in terms of its anti-
obesity utility.
120 The development of non-peptidic or DPP-IV
resistant GLP-1 receptor agonists have, therefore, been garnering
more recent attention, and may show more promise as anti-
obesity therapies. The GLP-1 analog, exendin-4, discovered from
the venom of the Gila monster, Heloderma suspectum,
122 is now
being investigated as an anti-obesity agent in non-diabetic
humans. Minor, yet adverse side effects, including nausea and
vomiting have, however, been reported,
120 thereby placing
limitations on its use in terms of a maximum tolerable dose.
The highly homologous, long half-life GLP-1 analog, liraglutide,
has also been demonstrated as a well-tolerated body weight-
reducing pharmacological agent in humans, yet transient nausea
remains to be the most common side effect.
117,123 Analogs with
greater similarity to the human form of GLP-1 are now in trial,
and determination of their efﬁcacy as anti-obesity agents is
ongoing.
120 Further to the currently investigated approaches,
future research aimed at better understanding the mechanisms
involved in endogenous GLP-1 production would be beneﬁcial.
With the known additive satiating effects of GLP-1 and PYY,
124
exploiting endogenous GLP-1 production may also yield a novel
combinatorial anti-obesity approach.
Oxyntomodulin
Early work in rats on a peptide with inhibitory action on stomach
oxyntic glands lead to the advent of the name OXM for the now
well established gut hormone.
125 OXM shares the same precursor
molecule as GLP-1, is co-secreted with GLP-1 following feeding,
and its release is also proportional to meal calorie content.
126
Centrally- and peripherally-administered OXM reduces food intake
and increases energy expenditure in rodents, and reductions in
body weight have been reported in response to chronic
injections.
127 Peripheral administration in humans increases
satiation and reduces food intake, with repeated injections
leading to decreases in body weight.
128 There has also been data
in support of OXM promoting increased energy expenditure in
humans.
129 The anorexigenic mechanism of action of OXM
remains unclear and its role in the pathogenesis of obesity
has been largely uninvestigated.
120 Furthermore, a speciﬁc OXM
receptor has yet to be discovered.
5 As injection of GLP-1 receptor
antagonists into the ARC has been demonstrated to block
the anorexigenic effects of OXM,
127 it has been proposed that
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binding afﬁnity is signiﬁcantly lower.
130 Furthermore, it has
recently been shown that OXM requires the GLP-1 receptor, as
its effect is abolished in GLP-1 receptor knockout mice.
131 It is also
possible that an unknown OXM receptor exists, yet it would
almost certainly share similarities with the GLP-1 receptor. Despite
the probable involvement of the GLP-1 receptor in OXM signaling,
the pathways are likely separate.
127 At equal concentrations,
both GLP-1 and OXM elicit anorexigenic effects, despite the large
disparity in GLP-1 receptor-binding afﬁnity.
129 Similar to GLP-1, the
potential therapeutic utility of OXM may, in part, be hindered due
to its inactivation by DPP-IV,
5 although its effects on food intake
in humans are more potent,
132 and it is reported to cause less
nausea than GLP-1.
15 A recent trial investigating the OXM analog
TKS1225 has demonstrated the increasing desirability to develop
OXM into an anti-obesity agent. Eliciting comparable satiating
effects to GLP-1,
133 along with the already well demonstrated
anti-obesity potential of GLP-1, OXM may equally present as a
strong gut hormone candidate for combating against the obesity
epidemic.
SUMMARY
The prevalence of obesity and its associated co-morbidities has
increased substantially in the last number of decades, and the
disease is now widely considered to be a global epidemic.
Currently, among approved anti-obesity therapies, only GI surgery
can effectively lead to substantial weight loss results, accom-
panied by long-term sustainability.
129 However, GI surgery has
largely been rendered impractical as a useful anti-obesity strategy,
in large part due to its high cost and rate of mortality. There has,
however, been increasingly convincing evidence that the resulting
weight loss following the surgery is due, at least in part, to an
alteration in the circulating levels and physiology of certain gut
hormones.
1,63 Stimulated release of anorexigenic peptides such
as CCK, PP, PYY, GLP-1, and OXM, and diminished release of the
orexigenic peptide ghrelin, have been documented.
63 In contrast
to some of the currently used, relatively non-speciﬁc drug
therapies, gut hormones function speciﬁcally on systems respon-
sible for appetite control.
129 In addition, due to their natural
physiological regulation of appetite, gut hormone-based therapies
are less likely to cause adverse side effects than some of the
currently approved drugs,
15 thus potentially offering a safer, more
attractive alternative approach to combat the obesity epidemic.
Although the gut-brain axis and a variety of hormone signaling
pathways have been emerging as potentially powerful anti-
obesity tools, the short half-life of many of the endogenous gut
hormones must be considered.
128,129 Receptor agonists and
alternative delivery routes have both been postulated to allow
for circumvention of this unfortunate characteristic, and to aid
in the future development of gut hormone-based anti-obesity
therapies.
15 In conclusion, continued research into the potential to
pharmacologically exploit endogenously occurring appetite-reg-
ulating gut hormones in an effort to regulate energy homeostasis
is required, but certainly holds great promise to lead to the
development of safe and effective anti-obesity treatments, and to
contribute to the effort of combating the rampant global rise in
obesity. The evidence presented herein strongly indicates that
obesity research and the development of weight loss or weight
management products should focus on the release and function
of gut hormones, in connection to their association with receptors
in the CNS, in particular the hypothalamus.
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